Wall Street is overwhelmingly bullish on the stocks in this article, with price targets suggesting significant upside potential. However, it’s worth remembering that analysts rarely issue sell ratings, partly because their firms often seek other business from the same companies they cover.
At StockStory, we look beyond the headlines with our independent analysis to determine whether these bullish calls are justified. Keeping that in mind, here is one stock likely to meet or exceed Wall Street’s lofty expectations and two where analysts may be overlooking some important risks.
Two Stocks to Sell:
Hasbro (HAS)
Consensus Price Target: $109.64 (22.8% implied return)
Credited with the creation of toys such as Mr. Potato Head and the Rubik’s Cube, Hasbro (NASDAQ: HAS) is a global entertainment company offering a diverse range of toys, games, and multimedia experiences for children and families.
Why Do We Steer Clear of HAS?
- Products and services aren’t resonating with the market as its revenue declined by 3.5% annually over the last five years
- Poor expense management has led to an operating margin of 9.7% that is below the industry average
- Earnings growth underperformed the sector average over the last five years as its EPS grew by just 2.7% annually
Hasbro’s stock price of $89.27 implies a valuation ratio of 14.8x forward P/E. Check out our free in-depth research report to learn more about why HAS doesn’t pass our bar.
GE HealthCare (GEHC)
Consensus Price Target: $82.50 (29.6% implied return)
Spun off from industrial giant General Electric in 2023 after over a century as its healthcare division, GE HealthCare (NASDAQ: GEHC) provides medical imaging equipment, patient monitoring systems, diagnostic pharmaceuticals, and AI-enabled healthcare solutions to hospitals and clinics worldwide.
Why Are We Wary of GEHC?
- Organic sales performance over the past two years indicates the company may need to make strategic adjustments or rely on M&A to catalyze faster growth
- Estimated sales growth of 4.4% for the next 12 months is soft and implies weaker demand
- Expenses have increased as a percentage of revenue over the last five years as its adjusted operating margin fell by 1.7 percentage points
GE HealthCare is trading at $63.64 per share, or 12.4x forward P/E. If you’re considering GEHC for your portfolio, see our FREE research report to learn more.
One Stock to Buy:
MercadoLibre (MELI)
Consensus Price Target: $2,265 (22.9% implied return)
Originally started as an online auction platform, MercadoLibre (NASDAQ: MELI) is a one-stop e-commerce marketplace and fintech platform in Latin America.
Why Will MELI Outperform?
- Monetization efforts are paying off as its average revenue per user has grown by 63.1% annually over the last two years
- Earnings per share grew by 35% annually over the last three years, massively outpacing its peers
- MELI is a free cash flow machine with the flexibility to invest in growth initiatives or return capital to shareholders, and its growing cash flow gives it even more resources to deploy
At $1,843 per share, MercadoLibre trades at 19x forward EV/EBITDA. Is now the time to initiate a position? Find out in our full research report, it’s free.
Stocks We Like Even More
ALSO WORTH WATCHING: Top 5 Momentum Stocks. The best time to own a great stock is when the market is finally noticing it. These aren’t just high-quality businesses. Something is happening with them right now. Elite fundamentals meet near-term momentum — both boxes checked at the same time.
Find out which stocks our AI platform is flagging this week. See this week’s Strong Momentum stocks — FREE. Get Our Strong Momentum Stocks for Free HERE.
Stocks that made our list in 2020 include now familiar names such as Nvidia (+1,460% between June 2020 and June 2025) as well as under-the-radar businesses like the once-micro-cap company Tecnoglass (+1,552% between June 2020 and June 2025). Find your next big winner with StockStory today.
